Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6387
Source ID: NCT02719756
Associated Drug: Metformin
Title: Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Diabetes Mellitus|Hypoglycemic Episodes
Interventions: DRUG: Metformin|DRUG: Dapagliflozin|DRUG: Metformin up-titration
Outcome Measures: Primary: Dynamics (delta from the baseline) of blood glucose variability - integral index of glycemia (LBGI-HBGI) after 3 months of therapy, 3 months | Secondary: Dynamics (delta from the baseline or % decrease of blood glucose level) of blood glucose variability (ADRR) after 3 months of therapy, 3 months|Dynamics of MAGE after 3 months of therapy, 3 months|Dynamic of glycaemia parameters: % of normoglycemia time after 3 months of therapy, 3 months|Dynamic of glycaemia parameters: % of hyperglycemia time after 3 months of therapy, 3 months|Dynamic of glycaemia parameters: % of hypoglycemia time after 3 months of therapy, 3 months|Dynamics of HbA1c (%) from baseline after 3 months of therapy, 3 months|Percentage of diabetes mellitus patients achieved individual target HbA1c, 3 months
Sponsor/Collaborators: Sponsor: Research Clinical Centre of the Russian Railways, JSC
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 100
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose:
Start Date: 2016-04
Completion Date: 2016-12
Results First Posted:
Last Update Posted: 2016-03-25
Locations: Research Clinical Centre of the Russian Railways, JSC, Moscow, 125993, Russian Federation
URL: https://clinicaltrials.gov/show/NCT02719756